New hope for psoriatic arthritis patients who run out of options
NCT ID NCT04632927
Summary
This study compared the effectiveness and safety of two injectable biologic drugs, secukinumab and ustekinumab, in adults with active psoriatic arthritis. It focused on patients whose symptoms were not adequately controlled by a common first-line biologic treatment. Over 28 weeks, researchers measured improvements in joint pain, swelling, skin psoriasis, and overall quality of life.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PSORIATIC ARTHRITIS are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Novartis Investigative Site
Rendsburg, Schleswig-Holstein, 24768, Germany
-
Novartis Investigative Site
Aachen, 52074, Germany
-
Novartis Investigative Site
Bad Bentheim, 48455, Germany
-
Novartis Investigative Site
Bad Doberan, 18209, Germany
-
Novartis Investigative Site
Berlin, 12435, Germany
-
Novartis Investigative Site
Berlin, 13125, Germany
-
Novartis Investigative Site
Berlin, 13353, Germany
-
Novartis Investigative Site
Bochum, 44791, Germany
-
Novartis Investigative Site
Cologne, 50937, Germany
-
Novartis Investigative Site
Cologne, 51149, Germany
-
Novartis Investigative Site
Cottbus, 03042, Germany
-
Novartis Investigative Site
Dresden, 01067, Germany
-
Novartis Investigative Site
Dresden, 01307, Germany
-
Novartis Investigative Site
Ehringshausen, 35630, Germany
-
Novartis Investigative Site
Erlangen, 91056, Germany
-
Novartis Investigative Site
Frankfurt, 60590, Germany
-
Novartis Investigative Site
Freiburg im Breisgau, 79106, Germany
-
Novartis Investigative Site
Gommern, 39245, Germany
-
Novartis Investigative Site
Göttingen, 37075, Germany
-
Novartis Investigative Site
Hamburg, 22391, Germany
-
Novartis Investigative Site
Herne, 44649, Germany
-
Novartis Investigative Site
Leipzig, 04103, Germany
-
Novartis Investigative Site
Magdeburg, 39104, Germany
-
Novartis Investigative Site
Magdeburg, 39110, Germany
-
Novartis Investigative Site
Mainz, 55131, Germany
-
Novartis Investigative Site
München, 81541, Germany
-
Novartis Investigative Site
Planegg, 82152, Germany
-
Novartis Investigative Site
Ratingen, 40878, Germany
Conditions
Explore the condition pages connected to this study.